Cell-free DNA promotes malignant transformation in non-tumor cells.

Autor: Souza AG; Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil. alingosouza@yahoo.com.br.; Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil. alingosouza@yahoo.com.br., Bastos VAF; Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil., Fujimura PT; Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil., Ferreira ICC; Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil., Leal LF; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil., da Silva LS; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil., Laus AC; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil., Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, SP, Brazil.; Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, Braga, Portugal.; 3ICVS/3B's-PT Government Associate Laboratory, Braga, Portugal., Martins MM; Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil., Santos PS; Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil., Corrêa NCR; Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil., Marangoni K; Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil., Thomé CH; Center for Cell Based Therapy, Hemotherapy Center of Ribeirão Preto, Ribeirão Preto, SP, Brazil., Colli LM; Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil., Goulart LR; Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil.; Department of Medical Microbiology and Immunology, University of California-Davis, Davis, USA., Goulart VA; Laboratory of Nanobiotechnology, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2020 Dec 10; Vol. 10 (1), pp. 21674. Date of Electronic Publication: 2020 Dec 10.
DOI: 10.1038/s41598-020-78766-5
Abstrakt: Cell-free DNA is present in different biological fluids and when released by tumor cells may contribute to pro-tumor events such as malignant transformation of cells adjacent to the tumor and metastasis. Thus, this study analyzed the effect of tumor cell-free DNA, isolated from the blood of prostate cancer patients, on non-tumor prostate cell lines (RWPE-1 and PNT-2). To achieve this, we performed cell-free DNA quantification and characterization assays, evaluation of gene and miRNA expression profiling focused on cancer progression and EMT, and metabolomics by mass spectrometry and cellular migration. The results showed that tumor-free cell DNA was able to alter the gene expression of MMP9 and CD44, alter the expression profile of nine miRNAs, and increased the tryptophan consumption and cell migration rates in non-tumor cells. Therefore, tumor cell-free DNA was capable of altering the receptor cell phenotype, triggering events related to malignant transformation in these cells, and can thus be considered a potential target for cancer diagnosis and therapy.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje